CYC116

Potent Aurora A/B inhibitor CAS# 693228-63-6

CYC116

Catalog No. BCC2181----Order now to get a substantial discount!

Product Name & Size Price Stock
CYC116: 5mg $46 In Stock
CYC116: 10mg Please Inquire In Stock
CYC116: 20mg Please Inquire Please Inquire
CYC116: 50mg Please Inquire Please Inquire
CYC116: 100mg Please Inquire Please Inquire
CYC116: 200mg Please Inquire Please Inquire
CYC116: 500mg Please Inquire Please Inquire
CYC116: 1000mg Please Inquire Please Inquire
Related Products
  • MLN8237 (Alisertib)

    Catalog No.:BCC2166
    CAS No.:1028486-01-2
  • SCH-1473759

    Catalog No.:BCC1934
    CAS No.:1094069-99-4
  • Reversine

    Catalog No.:BCC1892
    CAS No.:656820-32-5
  • AZD1152

    Catalog No.:BCC1393
    CAS No.:722543-31-9
  • XL228

    Catalog No.:BCC2058
    CAS No.:898280-07-4

Quality Control of CYC116

Number of papers citing our products

Chemical structure

CYC116

3D structure

Chemical Properties of CYC116

Cas No. 693228-63-6 SDF Download SDF
PubChem ID 6420138 Appearance Powder
Formula C18H20N6OS M.Wt 368.46
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
Chemical Name 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
SMILES CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
Standard InChIKey GPSZYOIFQZPWEJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of CYC116

DescriptionCYC116 is a potent inhibitor of Aurora A and B with Ki value of 8 nM and 9.2 nM, respectively.
TargetsAurora AAurora B    
IC508 nM9.2 nM    

CYC116 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

CYC116 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of CYC116

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.714 mL 13.57 mL 27.14 mL 54.28 mL 67.85 mL
5 mM 0.5428 mL 2.714 mL 5.428 mL 10.856 mL 13.57 mL
10 mM 0.2714 mL 1.357 mL 2.714 mL 5.428 mL 6.785 mL
50 mM 0.0543 mL 0.2714 mL 0.5428 mL 1.0856 mL 1.357 mL
100 mM 0.0271 mL 0.1357 mL 0.2714 mL 0.5428 mL 0.6785 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on CYC116

IC50: 44 and 19 nM respectively for Aurora A and B in cancer cells

Ki: 8.0 and 9.2 nM for aurora A and B, respectively

The aurora kinases are a family of serine-threonine kinases that interact with components of the mitotic apparatus and that regulate aspects of centrosome maturation, bipolar spindle assembly, chromosome segregation, and cytokinesis. CYC116 has been discoverd as a novel N-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitor.

In vitro: The anticancer effects of CYC116 were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora A and B kinases. Moreover, CYC116 was also assessed against other kinases [1].

In vivo: Preliminary in vivo assessment showed that CYC116 was orally bioavailable and possessed anticancer activity. The mean relative tumor volumes of mice receiving CYC116 at both dose levels were less than those of vehicle-treated mice for the duration of the study period [1].

Clinical trials: CYC116 is currently undergoing evaluation in Phase I clinical trials.

Reference:
[1] Wang S, Midgley CA, Scaërou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM.   Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010;53(11):4367-78.

Featured Products
New Products
 

References on CYC116

Matrine and CYC116 synergistically inhibit growth and induce apoptosis in multiple myeloma cells.[Pubmed:25804197]

Chin J Integr Med. 2015 Aug;21(8):635-9.

OBJECTIVE: To investigate whether CYC116 can potentiate matrine-dependent growth inhibition and apoptosis in multiple myeloma (MM) cells. METHODS: The dose response relationship of matrine to dexamethasone-resistant and dexamethasone-sensitive MM cells was first established. Myeloma RPMI8226 cells were treated with matrine alone or combined with CYC116 for 24 h. Cell proliferation was measured using an MTT assay and apoptosis induction was evaluated by flow cytometry. Activation of the caspase pathway and expression of apoptosis regulator proteins were detected by Western blotting. RESULTS: Matrine significantly induced growth arrest and apoptosis in both drug-resistant and drug-sensitive MM cells. Treatment with the combination of matrine and CYC116 had a stronger cytotoxic effect on MM cells than did single drug treatments. Enhanced apoptosis observed following the combined treatment of matrine and CYC116 was associated with higher levels of activation of caspase-9, caspase-3, and poly adenosine diphosphate ribose polymerase (PARP) and down-regulation of the anti-apoptotic proteins Bcl-2 and Mcl-1 and the signaling proteins p-Akt and nuclear factor kappaB (NF-kappaB). CONCLUSION: CYC116 enhances the growth inhibitory and apoptotic effects of matrine on MM cells.

Description

CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.

Keywords:

CYC116,693228-63-6,Natural Products,Aurora Kinase, buy CYC116 , CYC116 supplier , purchase CYC116 , CYC116 cost , CYC116 manufacturer , order CYC116 , high purity CYC116

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: